Introduction
This analysis examines the current position and future outlook for Shire in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-7 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Evaluate Shire's program of rationalization and global integration following its strategic review in 2003
Assess the impact of generic competition to Shire's Adderall franchise
Benchmark Shire's performance against key rivals in the ethical pharmaceutical sector
(0 items)
